May 24, 2017
Alcon has introduced SYSTANE ICAPS Chewable AREDS2 Eye Vitamin in the U.S. market, a supplement designed to support eye health in people with intermediate-to-advanced Age-Related Macular Degeneration (AMD).
It contains ingredients used in the Age-Related Eye Disease Study 2 (AREDS2), a clinical trial conducted by the National Eye Institute that evaluated the effects of various combinations of nutrients on the progression of AMD.
Alcon says the vitamin is formulated with six clinically proven nutrients based on clinical evidence from AREDS2.1 As compared with formulations based on the original AREDS study, the company notes that SYSTANE ICAPS Chewable AREDS2 Eye Vitamin has lower zinc levels and no beta-carotene.
According to Alcon, it is the first chewable vitamin formulation in the U.S. based on the AREDS2 study, and is packaged with an easy-open cap.
“The launch of SYSTANE ICAPS Chewable AREDS2 Eye Vitamin builds on the success Alcon’s ICAPS line of eye vitamin formulations, which are designed to support healthy eyes,” says Jeff Huffman, marketing director, OTC Marketing – Eye Drops & Vitamins. “This is a significant step forward in the Alcon eye vitamin portfolio and extends
the range of patients whose eye health needs can be met by our products, while also offering a flavorful, convenient chewable formula.”
The SYSTANE ICAPS Chewable AREDS2 Eye Vitamin contains the following nutrients:
• 500 mg vitamin C (as Ascorbic acid)
• 400 IU of vitamin E (as d-alpha-tocopheryl acetate)
• 25 mg of zinc (as Zinc oxide)
• 2 mg copper (as copper citrate)
• 10 mg lutein
• 2 mg zeaxanthin
Other Alcon eye vitamins include ICAPS Eye Vitamin Lutein & Omega-3 Formula, ICAPS Eye Vitamin Multivitamin Formula, ICAPS Eye Vitamin AREDS Formula and ICAPS Eye Vitamin Lutein & Zeaxanthin Formula.
SYSTANE ICAPS Chewable AREDS2 Eye Vitamin will be available in retail stores by June 1.
Reference
1. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA. 2013;309(19):2005-15.
